# Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non–Small Cell Lung Cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-of-crizotinib-among-different-types-of-ros1-fusion-partners-in-patients/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ziming Li,Lan Shen,Ding Ding,Jia Huang,Jie Zhang,Zhiwei Chen,Shun Lü |
| Citations | 121 |
| DOI | 10.1016/j.jtho.2018.04.016 |
| Fields | Environmental Science,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.jto.org/article/S1556086418305422/pdf |
| OpenAlex ID | https://openalex.org/W2800286167 |
| PMID | 29704675 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Lan Shen](https://scholariq.org/researchers/lan-shen/)

## Paper journal

- [Journal of Thoracic Oncology](https://scholariq.org/journals/journal-of-thoracic-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cytokine Signaling Pathways and Interactions](https://scholariq.org/topics/cytokine-signaling-pathways-and-interactions/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.